Home
Alerts
Search
Watchlists
Products
Aptus Pharma Ltd
APPL
BSE
₹ 385.50
0.77%
Last Updated:
29 Apr '26, 4:00 PM
Industry:
Pharma - Formulators
Aptus Pharma Ltd
APPL
BSE
₹ 385.50
0.77%
29 Apr '26, 4:00 PM
Industry
Pharma - Formulators
6M
Price
Charts
Documents
Quick Ratios
Edit Ratios
Mkt Cap
Market Capitalization
₹264Cr
Close
Close Price
₹385.50
Industry
Industry
Pharma - Formulators
PE
Price To Earnings
50.39
PS
Price To Sales
5.68
Revenue
Revenue
₹47Cr
Rev Gr TTM
Revenue Growth TTM
89.62%
PAT Gr TTM
PAT Growth TTM
49.03%
Peer Comparison
How does APPL stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
APPL
VS
Quarterly Results
Standalone
Numbers
Percentage
| Quarter | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| 10 | 15 | 14 | 32 | |
Growth YoY Revenue Growth YoY% | 47.3 | 117.6 | ||
| 8 | 12 | 11 | 28 | |
| 2 | 3 | 3 | 5 | |
OPM OPM% | 20.3 | 19.4 | 20.4 | 14.0 |
| 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 |
PBT PBTCr | 2 | 3 | 3 | 4 |
| 0 | 1 | 1 | 1 | |
| 1 | 2 | 2 | 3 | |
Growth YoY PAT Growth YoY% | 33.6 | 60.3 | ||
NPM NPM% | 13.4 | 12.1 | 12.2 | 8.9 |
| 0.0 | 0.0 | 3.5 | 4.2 |
Profit & Loss
Standalone
Numbers
Percentage
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
Revenue RevenueCr | 14 | 18 | 25 | 47 |
Growth Revenue Growth% | 28.5 | 37.5 | 89.6 | |
| 13 | 16 | 20 | 39 | |
| 1 | 2 | 5 | 7 | |
OPM OPM% | 4.5 | 8.7 | 19.7 | 16.0 |
| 0 | 0 | 0 | ||
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 |
PBT PBTCr | 0 | 1 | 4 | 6 |
| 0 | 0 | 1 | 2 | |
PAT PATCr | 0 | 1 | 3 | 5 |
Growth PAT Growth% | 310.8 | 288.4 | 49.0 | |
NPM NPM% | 1.4 | 4.5 | 12.6 | 9.9 |
| 1.3 | 5.3 | 6.4 | 7.8 |
Balance Sheet
Standalone
Numbers
Percentage
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
Equity Capital Equity CapitalCr | 0 | 0 | 5 |
Reserves ReservesCr | 1 | 1 | 2 |
| 3 | 4 | 12 | |
| 2 | 4 | 3 | |
| 6 | 10 | 22 | |
| 6 | 8 | 20 | |
| 1 | 2 | 2 | |
| 6 | 10 | 22 |
Cash Flow
Standalone
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 0 | -2 | -2 | -7 | |
| 0 | 0 | -1 | -6 | |
| 1 | 3 | 7 | 9 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 4 | -4 |
Free Cash Flow Free Cash FlowCr | -1 | -3 | -2 | |
CFO To PAT CFO To PAT% | -93.0 | -272.5 | -59.3 | -148.5 |
CFO To EBITDA CFO To EBITDA% | -29.2 | -140.6 | -37.9 | -92.2 |
Ratios
Standalone
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 240 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 51.8 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 5.1 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 10.3 |
EV To EBITDA EV To EBITDA | 2.7 | 2.8 | 1.1 | |
GPM GPM% | 65.7 | 61.8 | 63.2 | 54.1 |
OPM OPM% | 4.5 | 8.7 | 19.7 | 16.0 |
NPM NPM% | 1.4 | 4.5 | 12.6 | 9.9 |
ROCE ROCE% | 13.8 | 19.2 | 26.9 | |
ROE ROE% | 20.1 | 45.2 | 44.5 | |
ROA ROA% | 3.1 | 8.0 | 14.1 | |